Home > Market Research > Health Products > The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
The prevalence of asthma in 2005 across the US, Japan, France, Germany, Spain, Italy and the UK was estimated at 53.2m people, corresponding to a prevalence rate of 7.7%. The highest prevalence rate for asthma in any country in 2005 was 12.0% in the UK. It is forecast that by 2011, the total prevalence of asthma across the seven major markets will be 58.8m sufferers or 8.0% of the population.
COPD is only significantly prevalent in adults, a contrary situation to that of asthma, in which pediatric patients are estimated to represent some 35% of the total asthmatic patient population across the 7 major markets. 56.4m individuals are estimated to suffer from COPD across the seven major markets, although extremely low rates of diagnosis are thought to have resulted in a treated population of less than 10m individuals. Increasingly, COPD is becoming a major disease burden across the seven major markets, with a forecast patient population of 60.8m individuals by 2011, indicating high levels of future patient potential. Currently the treatment of asthma/COPD favors the use of beta-2 agonists and inhaled corticosteroids, with leukotriene antagonists and anticholinergics being positioned as additional therapies in either pediatric or last-line patients. With an estimated patient potential of 1.5bn in 2005, allergic rhinitis (AR) is associated with the largest disease burden of any major chronic respiratory disease by virtue of its high prevalence and its impacts on quality of life and productivity. It is believed that AR and asthma frequently co-exist and AR is a significant risk factor for asthma.
Across the seven major markets, the prevalence of AR is forecast to increase to 1.8bn individuals in 2011, driven by the effect of raised levels of allergenic exposure, in both indoor and outdoor environments.
Top of Page
Table of Contents
Executive Summary 10
Patient potential 10
Global market analysis 11
Analysis of future potential respiratory blockbusters 12
Leading players in the respiratory market 13
Chapter 1 Patient potential 16
Summary 16
Introduction 17
Asthma 17
Overview 17
Diagnosis, treatment and management 18
Epidemiology 22
Chronic Obstructive Pulmonary Disease (COPD) 24
Overview 24
Diagnosis, treatment and management 25
Epidemiology 27
Allergic rhinitis 30
Overview 30
Diagnosis, treatment and management 31
Epidemiology 34
Chapter 2 Global market analysis 38
Summary 38
Introduction 39
Respiratory market analysis by drug class 39
Leading respiratory brand dynamics 42
Asthma/COPD market analysis 45
Introduction 45
Asthma/COPD drug classes 46
Leading brands in the asthma/COPD market 49
SABA/LABA therapies 52
Leading brands in the global SABA/LABA market 52
Overview/market dynamics 52
Key brands analysis 53
Inhaled corticosteroids 60
Leading brands in the global ICS market 60
Overview/market dynamics 60
Key brands analysis 61
Combination LABA/ICS products 65
Leading brands in the global combination LABA/ICS market 65
Overview/market dynamics 65
Key brands analysis 66
Leukotriene antagonists 71
Leading brands in the global leukotriene antagonist market 71
Overview/market dynamics 71
Key brands analysis 72
Anticholinergics/anticholinergics combination products 74
Leading brands in the global anticholinergic market 74
Overview/market dynamics 74
Key brands analysis 75
Asthma/COPD class forecasts to 2011 78
Allergic rhinitis market analysis 79
Introduction 79
Allergic rhinitis drug classes 80
Leading brands in the allergic rhinitis market 83
Anti-histamines 85
Leading brands in the global antihistamines market 85
Overview/market dynamics 85
Key brands analysis 86
Nasal corticosteroids 90
Leading brands in the global nasal corticosteroid market 90
Overview/market dynamics 91
Key brands analysis 91
Allergic rhinitis class forecasts to 2011 95
Chapter 3 Analysis of future potential respiratory blockbusters 98
Summary 98
Introduction 99
Major approaches to R&D 100
Drug profiles 101
Phase II pipeline drugs 101
Super Advair (fluticasone/salmeterol) 101
EPI-12323 103
Phase III pipeline drugs 105
QAB149 (indacaterol) 105
Allermist/Avamys (fluticasone furoate) 107
Flutiform (formoterol/fluticasone) 109
Drugs in registration 111
arformoterol 111
Alvesco (ciclesonide) 113
Daxas (roflumilast) 117
Ariflo (cilomilast) 119
Recently marketed drugs 122
Xolair (omalizumab) 122
Asmanex (mometasone) 124
Forecast sales potential 125
Chapter 4 Leading players in the respiratory market 128
Summary 128
Introduction 129
Global market shares 130
GlaxoSmithKline 133
Marketed products 133
R&D compounds 135
Respiratory portfolio sales forecasts to 2011 136
Merck & Co. 137
Marketed products 137
R&D compounds 138
Respiratory portfolio sales forecasts to 2011 139
Boehringer Ingelheim 140
Marketed products 140
R&D compounds 141
Respiratory portfolio sales forecasts to 2011 141
AstraZeneca 142
Marketed products 142
R&D compounds 143
Respiratory portfolio sales forecasts to 2011 144
Schering-Plough 145
Marketed products 145
R&D compounds 146
Respiratory portfolio sales forecasts to 2011 147
Sanofi-Aventis 148
Marketed products 148
R&D compounds 149
Respiratory portfolio sales forecasts to 2011 150
Pfizer 151
Marketed products 151
R&D compounds 152
Respiratory portfolio sales forecasts to 2011 153
Novartis 154
Marketed products 154
R&D compounds 155
Respiratory portfolio sales forecasts to 2011 156
Chapter 5 Appendix 158
IMS sales data 158
Glossary 159
Index 161
List of Figures
Figure 1.1: Estimated proportion of patients presenting with asthma that are correctly diagnosed by physician visit 19
Figure 1.2: Typical treatment patterns in the treatment of asthma 21
Figure 1.3: Typical treatment patterns in COPD 27
Figure 1.4: Classification of allergic rhinitis 31
Figure 1.5: Treatment of allergic rhinitis across different stages of disease progression 32
Figure 2.6: Competitive dynamics of drug classes within the global respiratory market, 2005 41
Figure 2.7: Competitive dynamics of leading brands in the global respiratory market, 2005 44
Figure 2.8: Competitive dynamics of drug classes within the global asthma/COPD market, 2005 48
Figure 2.9: Competitive dynamics of leading brands in the global asthma/COPD market, 2005 51
Figure 2.10: Competitive dynamics of drug classes within the allergic rhinitis market, 2005 82
Figure 2.11: Competitive dynamics of leading brands in the AR market, 2005 84
Figure 3.12: Leading recently launched respiratory products and compounds in R&D, 2006 99
Figure 3.13: Prevailing R&D approaches, 2006 100
Figure 4.14: Key players in the global respiratory market, 2001 & 2005 132
List of Tables
Table 1.1: Estimated prevalence of asthma in across seven major markets, 2005 22
Table 1.2: Forecast epidemiology of asthma across the seven major markets, 2005-11 23
Table 1.3: Estimated prevalence of COPD in across seven major markets, 2005 28
Table 1.4: Forecast epidemiology of COPD across the seven major markets, 2005-11 29
Table 1.5: Estimated prevalence of allergic rhinitis in across seven major markets, 2005 35
Table 1.6: Forecast epidemiology of allergy rhinitis across the seven major markets, 2005-11 36
Table 2.7: Breakdown of the global respiratory market by drug class, 2001–05 40
Table 2.8: Leading products in the global respiratory market, 2004–05 42
Table 2.9: Breakdown of the global asthma/COPD market by drug class, 2001–05 46
Table 2.10: Leading asthma/COPD products in the global respiratory market, 2004–05 49
Table 2.11: Leading SABA/LABA brands in the global respiratory market, 2004–05 52
Table 2.12: Leading ICS brands in the global respiratory market, 2004–05 60
Table 2.13: Leading combination LABA/ICS brands in the global respiratory market, 2004–05 65
Table 2.14: Leading leukotriene antagonist brands in the global respiratory market, 2004–05 71
Table 2.15: Leading anticholinergic brands in the global respiratory market, 2004–05 74
Table 2.16: Sales forecasts for classes in the asthma/COPD market, 2005–11 78
Table 2.17: Breakdown of the global allergy rhinitis market by drug class, 2001–05 80
Table 2.18: Leading allergic rhinitis products in the global respiratory market, 2004–05 83
Table 2.19: Leading antihistamine brands in the global respiratory market, 2004–05 85
Table 2.20: Leading nasal corticosteroid brands in the global respiratory market, 2004–05 90
Table 2.21: Sales forecasts for allergic rhinitis classes, 2005–11 95
Table 3.22: Sales forecasts for promising pipeline and recently launched compounds in R&D, 2005–11 125
Table 4.23: Key players in the global respiratory market, 2001-05 130
Table 4.24: GSK’s marketed respiratory portfolio, 2004-05 133
Table 4.25: GSK’s respiratory R&D pipeline, 2006 135
Table 4.26: Forecast sales for GSK’s respiratory portfolio, 2005–11 136
Table 4.27: Merck & Co’s marketed respiratory portfolio, 2004-05 137
Table 4.28: Merck & Co.’s respiratory R&D pipeline, 2006 138
Table 4.29: Forecast sales for Merck & Co.’s respiratory portfolio, 2005–11 139
Table 4.30: Boehringer Ingelheim’s marketed respiratory portfolio, 2004-05 140
Table 4.31: Forecast sales for BI’s respiratory portfolio, 2005–11 141
Table 4.32: AstraZeneca’s marketed respiratory portfolio, 2004-05 142
Table 4.33: AstraZeneca’s respiratory R&D pipeline, 2006 143
Table 4.34: Forecast sales for AstraZeneca’s respiratory portfolio, 2005–11 144
Table 4.35: Schering-Plough’s marketed respiratory portfolio, 2004-05 145
Table 4.36: Schering-Plough’s respiratory R&D pipeline, 2006 146
Table 4.37: Forecast sales for Schering-Plough’s respiratory portfolio, 2005–11 147
Table 4.38: Sanofi-Aventis’ marketed respiratory portfolio, 2004-05 148
Table 4.39: Sanofi-Aventis’ respiratory R&D pipeline, 2006 149
Table 4.40: Forecast sales for Sanofi-Aventis’ respiratory portfolio, 2005–11 150
Table 4.41: Pfizer’s marketed respiratory portfolio, 2004-05 151
Table 4.42: Pfizer’s respiratory R&D pipeline, 2006 152
Table 4.43: Forecast sales for Pfizer’s respiratory portfolio, 2005–11 153
Table 4.44: Novartis’ marketed respiratory portfolio, 2004-05 154
Table 4.45: Novartis’ respiratory R&D pipeline, 2006 155
Table 4.46: Forecast sales for Novartis’ respiratory portfolio, 2005–11 156
For full details, please email jenniferc@cmsinfo.com
Top of Page
Buy now!
Top of Page
|
